Clinical trials: Drug Side Effect
Adverse Drug Events
Information Systems-enabled Outreach Program for Adverse Drug Events
One of the most common health care interventions in any healthcare setting is a medication prescription. Unfortunately, up to 25% of outpatient prescriptions are associated with adverse drug events (ADEs).
- Trial name
- ISTOP-ADE (NCT02059044)
- Testing
- ISTOP-ADE
- Where
- Canada
- Volunteers
- 614 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer, Cardiotoxicity
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
Breast cancer is a chronic disease that has seen a boom in research into its treatments, improvements and effects in recent decades.
- Conditions
- Breast Cancer, Cardiotoxicity, Autonomic Imbalance
- Trial name
- NCT05040867
- Testing
- Physical exercise program
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- GO fit Lab- Ingesport
ER+ Breast Cancer, HER2-negative Breast Cancer
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
This study is a pragmatic international, multicenter, randomized, open label 3- arm trial of standard care vs. two pharmacological interventions: duloxetine or furosemide in patients with stage I-III ER+/HER2- early breast cancer…
- Conditions
- ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- NCT06407401
- Testing
- Duloxetine 60 MG, Furosemide 40 mg, Booklet for healthy behaviors
- Volunteers
- 399 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Cardiac Toxicity
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications.
- Trial name
- BACCARAT (NCT02605512)
- Testing
- Subclinical cardiac lesions and biomarkers
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Sophie JACOB
Drug-Induced Liver Injury
A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis
We will conduct a randomized placebo controlled trial to determine whether administration of intravenous (IV) NAC to participants with TB DIH, in dosages similar to that used in paracetamol poisoning, can improve recovery from…
- Trial name
- NAC in TB DIH (NCT02182167)
- Testing
- IV N-acetylcysteine (NAC), Water
- Where
- 2 sites in South Africa
- Volunteers
- 102 people
- Sponsor
- University of Cape Town
Kidney Transplant Dysfunction
Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients
The purpose of this study is to determine if measuring the level of a protein called Kidney Injury Molecule-1 (KIM-1) in the urine will help healthcare providers detect any problems with the transplanted kidney before the…
- Trial name
- NCT00805571
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Viral Pneumonia, Serotonin Syndrome
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
- Conditions
- Viral Pneumonia, Serotonin Syndrome, Platelet Dysfunction
- Trial name
- NCT04820751
- Testing
- Cyproheptadine Hydrochloride 4 MG
- Volunteers
- 200 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Depression, Adverse Reaction to Drug
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
- Trial name
- NCT00817375
- Testing
- SSRI treated group, non-SSRI treated group
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Behavioral Activation, Major Depressive Disorder
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder…
- Conditions
- Behavioral Activation, Major Depressive Disorder, Anxiety Disorders, Antidepressant Drug Adverse Reaction
- Trial name
- PGx-SImBA (NCT06763081)
- Testing
- Not applicable- observational study
- Where
- 2 sites in Canada
- Volunteers
- 160 people
- Sponsor
- University of Manitoba
Solid Tumor, Capecitabine
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Capecitabine is one of the most active agents in the treatment of many kinds of solid tumors. However, variability in toxicity and response remains a major problem for patients receiving capecitabine.
- Conditions
- Solid Tumor, Capecitabine, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetics
- Trial name
- NCT03258099
- Testing
- detection of genotype
- Where
- 7 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Cui Yimin
Cardiotoxicity
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
- Trial name
- NCT07663357
- Where
- 6 sites in Brazil
- Volunteers
- 1,000 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Adverse Drug Event
Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention
Reducing medications and associated side effects in older adults: an electronic hospital-based intervention
- Trial name
- NCT03272607
- Testing
- Deprescribing opportunities
- Where
- 7 sites in Canada
- Volunteers
- 6,582 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Drug Induced Liver Injury, Chronic Liver Disease
Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease
DILI is an underdiagnosed and under appreciated causal or contributing factor to liver injury. DILI can mimics features of the entire spectrum of acute and chronic liver disease.
- Trial name
- NCT06797011
- Testing
- High volume Plasma Exchange, Standard Medical Treatment
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Medication Safety
Pharmacist and Data Driven Quality Improvement in Primary Care
P-DQIP is an intervention to improve prescribing safety in primary care. The 'intervention' is a health board quality improvement programme that will be implemented across all practices in one National Health Service (NHS) board…
- Trial name
- P-DQIP (NCT03747107)
- Testing
- P-DQIP
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- University of Dundee
Cardiotoxicity, Cardiomyopathies
The Cardio-Oncology Breast Cancer Study
The main objective of this randomized controlled trial is to test the association between standard cardiac risk factors, biomarkers and parameters of echocardiography, electrocardiography, and cardiac magnetic resonance imaging…
- Conditions
- Cardiotoxicity, Cardiomyopathies, Breast Cancer
- Trial name
- COBC (NCT02571894)
- Testing
- Subclinical cardiotoxicity surveillance and treatment
- Where
- Sweden
- Volunteers
- 320 people
- Sponsor
- Karolinska University Hospital
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenia
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.
- Trial name
- ITP-RITUX (NCT01101295)
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Henri Mondor University Hospital
Adverse Reaction
Knowledge and Practices of ADR Reporting in LMICs
The reported literature suggests that knowledge about pharmacovigilance is on a lower side and ADR reporting is not common in developing countries.
- Trial name
- NCT04301219
- Where
- Pakistan
- Volunteers
- 1,500 people
- Sponsor
- Getz Pharma
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries.
- Trial name
- NCT07875322
- Testing
- Antituberculosis drugs Group
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University